Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

    1.1. Report Overview

2. Globoid Cell Leukodystrophy (Krabbe Disease) - Overview

3. Executive Summary

4. Globoid Cell Leukodystrophy (Krabbe Disease): Pipeline Assessment

    4.1. By Stage of Development

    4.2. By Route of Administration

    4.3. By Drug Class

    4.4. By Molecule Type

    4.5. By Therapy Area / Indication

    4.6. By Drug Target

    4.7. By Sponsor

5. Globoid Cell Leukodystrophy (Krabbe Disease): Company & Drug Profiles

    5.1. Clinical Stage

        5.1.1. BIOKRABBE – Centogene AG Rostock

            5.1.1.1. Company Overview

            5.1.1.2. Product Description

            5.1.1.3. R&D Status & Development Activities

            5.1.1.4. Mechanism of Action

            5.1.1.5. Molecule Type

            5.1.1.6. Stage of Development

            5.1.1.7. Indications

            5.1.1.8. Route of Administration

            5.1.1.9. Funding

        5.1.2. Campath-1H – Masonic Cancer Center, University of Minnesota

            5.1.2.1. Company Overview

            5.1.2.2. Product Description

            5.1.2.3. R&D Status & Development Activities

            5.1.2.4. Mechanism of Action

            5.1.2.5. Molecule Type

            5.1.2.6. Stage of Development

            5.1.2.7. Indications

            5.1.2.8. Route of Administration

            5.1.2.9. Funding

        5.1.3. MGTA-456 – Magenta Therapeutics

            5.1.3.1. Company Overview

            5.1.3.2. Product Description

            5.1.3.3. R&D Status & Development Activities

            5.1.3.4. Mechanism of Action

            5.1.3.5. Molecule Type

            5.1.3.6. Stage of Development

            5.1.3.7. Indications

            5.1.3.8. Route of Administration

            5.1.3.9. Funding

        5.1.4. Others

    5.2. Preclinical

        5.2.1. Company Overview

        5.2.2. Product Description

        5.2.3. R&D Status & Development Activities

        5.2.4. Mechanism of Action

        5.2.5. Molecule Type

        5.2.6. Indications

        5.2.7. Route of Administration

        5.2.8. Funding

6. Globoid Cell Leukodystrophy (Krabbe Disease): An Overview on Dormant & Discontinued Pipeline Candidates

    6.1. Overview

    6.2. Product Description

    6.3. Reason for Discontinuation

7. Globoid Cell Leukodystrophy (Krabbe Disease): Additional Key Insights

    7.1. Epidemiology Overview: Globoid Cell Leukodystrophy (Krabbe Disease)

    7.2. Current Market Scenario: Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics

8. Globoid Cell Leukodystrophy (Krabbe Disease): News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.